心脏监测设备制造商iRhythm Technologies Inc.（IRTC）周四盘后股价大涨13.43%，主要受益于公司发布的第二季度财报优于市场预期。
根据公司公布的财报，截至6月30日的第二季度，iRhythm Technologies调整后每股亏损0.44美元，优于分析师平均预期的0.48美元亏损。公司营收达到1.8669亿美元，同比增长26.1%，同样超过分析师预期的1.7394亿美元。这一强劲的业绩表现显示了公司在心脏监测技术市场的持续增长和竞争力。
值得注意的是，尽管公司仍处于亏损状态，但亏损幅度明显收窄。相比去年同期每股0.61美元的亏损，本季度的表现显示出公司在控制成本和提高运营效率方面取得了进展。目前，分析师对iRhythm Technologies保持乐观态度，平均评级为"买入"。在13位分析师中，12位给予"强烈买入"或"买入"评级，1位给予"持有"评级，没有"卖出"或"强烈卖出"评级。分析师对公司未来12个月的目标价中位数为147.00美元，较最新收盘价140.08美元高出约4.7%，反映出市场对公司未来增长前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.